Table 3 Follow-ups during hospitalization and after discharge of patients with COVID-19
All patients | ^Wuhan | ^Non-Wuhan | p value | |
|---|---|---|---|---|
^Follow-ups during hospitalization: No., (%) | ||||
Follow up 1 (4 days after admission) | ||||
Progression | 31/53 (58.5%) | 20/30 (66.7%) | 11/23 (47.8%) | 0.168|| |
Improvement | 22/53 (41.5%) | 10/30 (33.3%) | 12/23 (52.2%) | |
Follow up 2 (8 days after admission) | ||||
Progression | 8/46 (17.4%) | 8/26 (30.8%) | 0/20 | 0.006||* |
Improvement | 38/46 (82.6%) | 18/26 (69.2%) | 20/20 (100%) | |
Mean length of stay hospital: Mean (SD) | ||||
13.9 (4.1) | 14.5 (4.7) | 13.2 (3.2) | 0.213‡ | |
Median interval between symptom onset and discharge: Median (IQR) | ||||
19.0 (16.0–23.0) | 20.0 (15.8–23.3) | 18.0 (16.0–20.0) | 0.171‡‡ | |
^Follow-ups after discharge: No., (%) | ||||
Follow up 1 (2 weeks after discharge) | ||||
Partly absorption of lesions | 41/45 (91.1%) | 25/25 (100%) | 16/20 (80%) | 0.033||* |
Complete absorption of lesions | 4/45 (8.9%) | 0/25 | 4/20 (20%) | |
Follow up 2 (4 weeks after discharge) | ||||
Partly absorption of lesions | 4/18 (22.2%) | 3/12 (25%) | 1/6 (16.7%) | 1.000|| |
Complete absorption of lesions | 14/18 (77.8%) | 9/12 (75%) | 5/6 (83.3%) | |